Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05722418
Status:
RECRUITING
Last Update Posted:
2024-05-06
First Post:
2022-12-19
Brief Title:
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RelapsedRefractory Multiple Myeloma
Sponsor:
Caribou Biosciences Inc
Organization:
Caribou Biosciences Inc
Study Overview
Official Title:
A Phase 1 Multicenter Open-Label Study of CB-011 a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RelapsedRefractory Multiple Myeloma CaMMouflage Trial
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CaMMouflage
Brief Summary:
This is a Phase 1 study to evaluate the safety of CB-011 the study treatment an allogeneic chimeric antigen receptor CAR-T cell therapy that targets the B cell maturation antigen BCMA to determine the best dose of CB-011 and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back relapsed or that is no longer responding to other treatment refractory
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None